COVID-19 vaccination among pregnant people in the United States: a systematic review

Rawal, Smita; TACKETT, Randall L.; Stone, Rebecca H.; Young, Henry N.

doi:10.1016/j.ajogmf.2022.100616

Cited by 50 publications

(67 citation statements)

References 68 publications

(133 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study supports the previously published literature regarding COVID‐19 vaccination in pregnancy and its importance in preventing severe illness with no major increase in adverse pregnancy or neonatal outcomes. 14 , 29 Moreover, pregnant patients should be encouraged not to delay vaccination till the postpartum period as studies so far have not shown increased risk of pregnancy loss or any other adverse perinatal outcomes when vaccine is given during pregnancy. 30 , 31 , 32 …”

Section: Discussionmentioning

confidence: 99%

“…Our study supports the previously published literature regarding COVID-19 vaccination in pregnancy and its importance in preventing severe illness with no major increase in adverse pregnancy or neonatal outcomes. 14,29 Moreover, pregnant patients should be encouraged not to delay vaccination till the postpartum period as studies so far have not shown increased risk of pregnancy loss or any other adverse perinatal outcomes when vaccine is given during pregnancy. [30][31][32] As stated earlier, with pregnant patients were excluded from the original vaccine trials, more prospective studies are needed in pregnancy to strengthen the existing evidence supporting the efficacy and safety of the vaccine in our population.…”

Section: Clinical and Research Implicationsmentioning

confidence: 99%

See 1 more Smart Citation

Decreased severity of COVID‐19 in vaccinated pregnant individuals during predominance of different SARS‐CoV‐2 variants

Eid

Abdelwahab

Williams

et al. 2022

American J Rep Immunol

View full text Add to dashboard Cite

Problem: Since the start of the pandemic, Pregnant individuals have been disproportionately affected by the severe acute respiratory syndrome coronavirus 2. Vaccination has been shown to be protective against severe disease. However, data on effectiveness of vaccine in reducing disease severity are limited in pregnant individuals who later developed COVID-19. Method of study: This is a single academic center retrospective cohort study of pregnant individuals who tested positive for COVID-19 from December 2020 through January 2022. The cohort was divided into two groups based on vaccination status.The primary outcome of our study was progression to severe or critical disease. A secondary analysis was performed based on the timeframes of predominance of different variants of SARS-CoV-2, to determine whether the effect of vaccination was different during these epochs.Results: Our cohort included 472 patients among which 125 (26.5%) were vaccinated and 347 were unvaccinated. None of the patients in the vaccinated group who later developed COVID-19 progressed to severe or critical disease compared to 7.2% in the unvaccinated one (p < .01). Similarly, after adjusting for medical comorbidities, obesity, receipt of monoclonal antibodies, and trimester at diagnosis, vaccinated individuals who later developed COVID-19 were less likely to be admitted to the hospital (1.6% vs. 14.7%, aOR .14, 95% CI .22-.47) compared with unvaccinated ones. Conclusion:Vaccination against SARS-CoV-2 in pregnant individuals who later develop a breakthrough infection, is associated with decreased progression to severe or critical COVID-19, and need for hospital and ICU admissions. Vaccination is specifically effective during the predominance of the more severe Delta variant.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Clinical and Research Implicationsmentioning

confidence: 99%

Decreased severity of COVID‐19 in vaccinated pregnant individuals during predominance of different SARS‐CoV‐2 variants

Eid

Abdelwahab

Williams

et al. 2022

American J Rep Immunol

View full text Add to dashboard Cite

show abstract

“…However, two systematic reviews found that reactogenicity is similar in pregnant women and the general population, abortion rates are similar in vaccinated and nonvaccinated pregnant women studied before the COVID-19 pandemic, and anti-SARS-CoV-2 immunoglobulins are transferred through the placenta and the breast milk to newborns, providing protective immunity [ 12 , 13 ]. Moreover, according to a systematic review of studies in the USA, pregnant women have the same risk of adverse pregnancy or neonatal outcomes as unvaccinated pregnant women [ 14 ]. In general, COVID-19 vaccination produces immune responses during pregnancy and does not cause vaccine-related adverse events [ 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

Uptake of COVID-19 Vaccines among Pregnant Women: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

Mass vaccination against COVID-19 is essential to control the pandemic. COVID-19 vaccines are now recommended during pregnancy to prevent adverse outcomes. With this review, we aimed to evaluate the evidence in the literature regarding the uptake of COVID-19 vaccinations among pregnant women. A comprehensive search was performed in PubMed, Medline, Scopus, ProQuest, Web of Science, CINAHL, and medRxiv from inception to 23 March 2022. We performed a meta-analysis to estimate the overall proportion of pregnant women vaccinated against COVID-19. We found 11 studies including 703,004 pregnant women. The overall proportion of pregnant women vaccinated against COVID-19 was 27.5% (95% CI: 18.8–37.0%). Predictors of COVID-19 vaccination uptake were older age, ethnicity, race, trust in COVID-19 vaccines, and fear of COVID-19 during pregnancy. Mistrust in the government, diagnosis of COVID-19 during pregnancy, and fears about the safety and side effects of COVID-19 vaccines were reasons for declining vaccination. The global COVID-19 vaccination prevalence in pregnant women is low. A large gap exists in the literature on the factors influencing the decision of pregnant women to be vaccinated against COVID-19. Targeted information campaigns are essential to increase vaccine literacy among pregnant women.

show abstract

“…However, two systematic reviews found that reactogenicity is similar in pregnant women and the general population, abortion rate is similar in vaccinated and non-vaccinated pregnant women studied before the COVID-19 pandemic, and anti-SARS-CoV-2 immunoglobulins are transferred through the placenta and the breast milk to the newborns, providing protective immunity (Falsaperla et al, 2021; Fu et al, 2022). Moreover, according to a systematic review with studies in the USA, pregnant women have the same risk of adverse pregnancy or neonatal outcomes with unvaccinated pregnant women (Rawal et al, 2022). In general, COVID-19 vaccination produces immune responses during pregnancy and does not cause major negative outcomes.…”

Section: Introductionmentioning

confidence: 99%

Uptake of COVID-19 vaccines among pregnant women: a systematic review and meta-analysis

Galanis

Vraka

Σίσκου

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Mass vaccination against the COVID-19 is essential to control the pandemic. COVID-19 vaccines are recommended now during pregnancy to prevent adverse outcomes. Objective: To evaluate the evidence from the literature regarding the uptake of COVID-19 vaccination among pregnant women. Methods: We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. We searched PubMed, Medline, Scopus, ProQuest, Web of Science, CINAHL, and a pre-print service (medRxiv) from inception to March 23, 2022. We included quantitative studies reporting COVID-19 vaccination uptake among pregnant women, studies that examine predictors of COVID-19 vaccination uptake and studies that examine reasons for decline of vaccination. We performed meta-analysis to estimate the overall proportion of vaccinated pregnant women against the COVID-19. Results: We found 11 studies including 703,004 pregnant women. The overall proportion of vaccinated pregnant women against the COVID-19 was 27.5% (95% CI: 18.8-37.0%). The pooled proportion for studies that were conducted in Israel was higher than the proportion for studies that were conducted in USA and other countries. Predictors of COVID-19 vaccination uptake were older age, ethnicity, race, trust in COVID-19 vaccines, and fear of COVID-19 during pregnancy. On the other hand, mistrust in the government, diagnosis with COVID-19 during pregnancy, and worry about the safety and the side effects of the COVID-19 vaccines were reasons for decline of vaccination. Conclusions: The global COVID-19 vaccination prevalence in pregnant women is low. Τhere is a large gap in the literature on the factors influencing the decision of pregnant women to be vaccinated against the COVID-19. Targeted information campaigns are essential to improve trust and build vaccine literacy among pregnant women. Given the ongoing high case rates and the known increased risks of COVID-19 in pregnant women, our findings could help policy makers to improve the acceptance rate of COVID-19 vaccines in pregnant women especially in vulnerable subgroups.

show abstract

COVID-19 vaccination among pregnant people in the United States: a systematic review

Cited by 50 publications

References 68 publications

Decreased severity of COVID‐19 in vaccinated pregnant individuals during predominance of different SARS‐CoV‐2 variants

Decreased severity of COVID‐19 in vaccinated pregnant individuals during predominance of different SARS‐CoV‐2 variants

Uptake of COVID-19 Vaccines among Pregnant Women: A Systematic Review and Meta-Analysis

Uptake of COVID-19 vaccines among pregnant women: a systematic review and meta-analysis

Contact Info

Product

Resources

About